Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional)
Funding to develop and study mobile health technology for low and middle-income countries, promoting innovation, evidence-based practice, and research capacity in global health.
This grant is no longer accepting proposals
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health
Due Dates: February 21, 2025 (Letter of Intent) | March 21, 2025 (Full Application) | February 20, 2026 (Letter of Intent) | March 20, 2026 (Full Application)
Funding Amounts: R21: up to $125,000 direct costs/year (max 2 years); R33: up to $200,000 direct costs/year (max 3 years); total project period up to 5 years.
Summary: Supports development, validation, and evaluation of innovative mobile health (mHealth) interventions or tools for low- and middle-income countries (LMICs), with required U.S.-LMIC institutional partnerships.
Key Information: U.S. applicants must include LMIC researchers as key personnel; SMS-only interventions are not responsive.
Description
This funding opportunity supports exploratory and developmental research on mobile health (mHealth) technologies specifically designed for low- and middle-income countries (LMICs). The program aims to catalyze innovation through multidisciplinary research, develop an evidence base for mHealth interventions to improve clinical and public health outcomes, and strengthen mHealth research capacity in LMICs. Projects must utilize new or emerging technology, platforms, systems, or analytics, and should address the unique needs and constraints of LMIC settings.
Applicants must propose partnerships between at least one U.S. institution and one LMIC institution. U.S. applicants are required to include LMIC researchers as key personnel. The program uses a phased R21/R33 mechanism: the R21 phase supports technology development and feasibility studies, while the R33 phase (contingent on milestone completion and program priorities) supports validation, larger-scale feasibility, and effectiveness studies.
